+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LATAM Pain Management Drugs Market by Drug Class, Indication: Regional Opportunity Analysis and Industry Forecast, 2019-2027

  • ID: 5214838
  • Report
  • October 2020
  • Region: Global
  • 235 pages
  • Allied Analytics LLP

The LATAM pain management drugs market was valued at $2,683. 82 million in 2019, and is projected to reach $3,383. 20 million by 2027, registering a CAGR of 3. 5% from 2020 to 2027.



Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Moreover, different disorders may cause discomforts, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer.

The length of pain ranges from acute pain for the short term to chronic pain for the long term. Acute pain is a sudden onset of pain while chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available that provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

The rise in the geriatric population is the major factor that drives the growth of the LATAM pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, the surge in the prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth in Latin America. Furthermore, The rise in a number of surgical procedures and The rise in healthcare expenditure are expected to fuel the growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth in Latin America. The LATAM pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics.

On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, fibromyalgia, bone fracture, muscle sprain, acute appendicitis, and others. By region, it is analyzed across Brazil, Argentina, Colombia, Peru, Chile, Ecuador, Panama, and rest of Latin America.

The key players operating in the LATAM pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Drug class segment review

By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess the highest growth rate during the forecast period.

Segment review

By indication, the neuropathic pain segment accounted for a majority of the market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of a large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period, owing to the increase in a number of surgeries in Latin America and The rise in prevalence of chronic diseases that lead to back pain.

Brazil accounted for the majority of the market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. The rise in the number of drug abuse cases and the addictive nature of opioids has decreased the use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other hand, Argentina is expected to experience the highest growth rate during the forecast period, mainly attributable to the presence of larger patient pool and an increase in healthcare expenditure in the region.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the LATAM pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.
  • The market forecast is studied from 2020 to 2027
  • Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids
  • Nonnarcotic Analgesics

By Indication

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia
  • Bone fracture
  • Muscle sprain
  • Acute appendicitis
  • Others

By Region

  • LATAM
  • Brazil
  • Argentina
  • Colombia
  • Ecuador
  • Panama
  • Chile
  • Peru
  • Rest of Latin America

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Eli Lilly & Company
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mylan NV.
  • Novartis AG
  • Pfizer, Inc.
  • Axon
  • Sanofi
  • GRÜNENTHAL

OTHER PROMINENT MARKET PLAYERS

  • Allergen Inc.
  • Bayer AG
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sorrento Therapeutics
  • Valeant Pharmaceuticals International Inc.
  • WEX Pharmaceuticals
  • Zynerba Pharmaceuticals.
Note: Product cover images may vary from those shown
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Top Player Positioning
3.4. Porter’S Five Force Analysis for Latam
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. The Rise in Incidences of Chronic Diseases
3.5.1.2. Favorable Regulatory Scenario
3.5.1.3. Increase in Geriatric Population
3.5.2. Restraints
3.5.2.1. Availability of Alternative Therapies
3.5.2.2. Drug Exploitation
3.5.2.3. Patent Expiration of Prescription Drugs
3.5.3. Opportunities
3.5.3.1. Advancements in Drug Development
3.5.3.2. Untapped Markets in Developing Economies
3.6. Covid-19 Impact Analysis for Latam Pain Management Drugs
3.7. Molecule Information for Latam
3.7.1. Brazil
3.7.1.1. NSAIDs
3.7.1.2. Opioids
3.7.2. Argentina
3.7.2.1. NSAIDs
3.7.2.2. Opioids
3.7.3. Colombia
3.7.3.1. NSAIDs
3.7.3.2. Opioids
3.7.4. Peru
3.7.4.1. NSAIDs
3.7.4.2. Opioids
3.7.5. Chile
3.7.5.1. NSAIDs
3.7.5.2. Opioids
3.7.6. Ecuador
3.7.6.1. NSAIDs
3.7.6.2. Opioids
3.7.7. Panama
3.7.7.1. NSAIDs
3.7.7.2. Opioids

Chapter 4: Latam Pain Management Drugs Market, by Drug Class
4.1. Overview
4.1.1. Market Size and Forecast
4.2. NSAIDs
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Country
4.3. Anesthetics
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Country
4.4. Anticonvulsants
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Country
4.5. Antimigraine Drug
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Country
4.6. Antidepressant Drugs
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Country
4.7. Opioids
4.7.1. Key Market Trends, Growth Factors, and Opportunities
4.7.2. Market Size and Forecast, by Country
4.8. Non-Narcotic Analgesics
4.8.1. Key Market Trends, Growth Factors, and Opportunities
4.8.2. Market Size and Forecast, by Country

Chapter 5: Latam Pain Management Drugs Market, by Indication
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Arthritic Pain
5.2.1. Market Size and Forecast, by Country
5.3. Neuropathic Pain
5.3.1. Market Size and Forecast, by Country
5.4. Cancer Pain
5.4.1. Market Size and Forecast, by Country
5.5. Chronic Back Pain
5.5.1. Market Size and Forecast, by Country
5.6. Post-Operative Pain
5.6.1. Market Size and Forecast, by Country
5.7. Migraine
5.7.1. Market Size and Forecast, by Country
5.8. Fibromyalgia
5.8.1. Market Size and Forecast, by Country
5.9. Bone Fracture
5.9.1. Market Size and Forecast, by Country
5.10. Muscle Sprain/Strain
5.10.1. Market Size and Forecast, by Country
5.11. Acute Appendicitis
5.11.1. Market Size and Forecast, by Country
5.12. Others
5.12.1. Market Size and Forecast, by Country

Chapter 6: Latam Pain Management Drugs Market, by Country
6.1. Overview
6.2. Latam (Latin America)
6.2.1. Key Market Trends, Growth Factors, and Opportunities
6.2.2. Latam (Latin America)
6.2.2.1. Market Size and Forecast, by Country
6.2.2.2. Market Size and Forecast, by Drug Class
6.2.2.3. Market Size and Forecast, by Indication
6.2.2.4. Brazil
6.2.2.4.1. Market Size and Forecast, by Drug Class
6.2.2.4.2. Market Size and Forecast, by Indication
6.2.2.5. Argentina
6.2.2.5.1. Market Size and Forecast, by Drug Class
6.2.2.5.2. Market Size and Forecast, by Indication
6.2.2.6. Colombia
6.2.2.6.1. Market Size and Forecast, by Drug Class
6.2.2.6.2. Market Size and Forecast, by Indication
6.2.2.7. Peru
6.2.2.7.1. Market Size and Forecast, by Drug Class
6.2.2.7.2. Market Size and Forecast, by Indication
6.2.2.8. Chile
6.2.2.8.1. Market Size and Forecast, by Drug Class
6.2.2.8.2. Market Size and Forecast, by Indication
6.2.2.9. Ecuador
6.2.2.9.1. Market Size and Forecast, by Drug Class
6.2.2.9.2. Market Size and Forecast, by Indication
6.2.2.10. Panama
6.2.2.10.1. Market Size and Forecast, by Drug Class
6.2.2.10.2. Market Size and Forecast, by Indication
6.2.2.11. Rest of Latin America
6.2.2.11.1. Market Size and Forecast, by Drug Class
6.2.2.11.2. Market Size and Forecast, by Indication

Chapter 7: Company Profiles
7.1. Abbott Laboratories
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Axon Pharma
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Product Portfolio
7.3. Eli Lily and Company
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3.6. Key Strategic Moves and Developments
7.4. Grünenthal
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Product Portfolio
7.4.4. Business Performance
7.4.5. Key Strategic Moves and Developments
7.5. GlaxoSmithKline plc (Gsk)
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves and Developments
7.6. Johnson & Johnson
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Merck & Co. Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.7.6. Key Strategic Moves and Developments
7.8. Mylan N. V.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.8.6. Key Strategic Moves and Developments
7.9. Novartis International AG
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Pfizer Inc.
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
7.10.6. Key Strategic Moves and Developments
7.11. Sanofi
7.11.1. Company Overview
7.11.2. Company Snapshot
7.11.3. Operating Business Segments
7.11.4. Product Portfolio
7.11.5. Business Performance

List of Tables
Table 01. Brazil NSAIDs Market, by Molecule, 2019, ($Million)
Table 02. Brazil Opioids Market, by Molecule, 2019, ($Million)
Table 03. Argentina NSAIDs Market, by Molecule, 2019, ($Million)
Table 04. Argentina Opioids Market, by Molecule, 2019, ($Million)
Table 05. Colombia NSAIDs Market, by Molecule, 2019, ($Million)
Table 06. Colombia Opioids Market, by Molecule, 2019, ($Million)
Table 07. Peru NSAIDs Market, by Molecule, 2019, ($Million)
Table 08. Peru Opioids Market, by Molecule, 2019, ($Million)
Table 09. Chile NSAIDs Market, by Molecule, 2019, ($Million)
Table 10. Chile Opioids Market, by Molecule, 2019, ($Million)
Table 11. Ecuador NSAIDs Market, by Molecule, 2019, ($Million)
Table 12. Ecuador Opioids Market, by Molecule, 2019, ($Million)
Table 13. Panama NSAIDs Market, by Molecule, 2019, ($Million)
Table 14. Panama Opioids Market, by Molecule, 2019, ($Million)
Table 15. Latam Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 16. Latam Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 17. Latam Pain Management Drugs Market, by NSAIDs, by Country, 2019-2027 ($Million)
Table 18. Latam Pain Management Drugs Market, by NSAIDs, by Country, 2019-2027 (Million Units)
Table 19. Latam Pain Management Drugs Market, by Anesthetics, by Country, 2019-2027 ($Million)
Table 20. Latam Pain Management Drugs Market, by Anesthetics, by Country, 2019-2027 (Million Units)
Table 21. Latam Pain Management Drugs Market, by Anticonvulsants, by Country, 2019-2027 ($Million)
Table 22. Latam Pain Management Drugs Market, by Anticonvulsants, by Country, 2019-2027 (Million Units)
Table 23. Latam Pain Management Drugs Market, by Antimigraine Agents, by Country, 2019-2027 ($Million)
Table 24. Latam Pain Management Drugs Market, by Antimigraine Agents, by Country, 2019-2027 (Million Units)
Table 25. Latam Pain Management Drugs Market, by Antidepressants, by Country, 2019-2027 ($Million)
Table 26. Latam Pain Management Drugs Market, by Antidepressants, by Country, 2019-2027 (Million Units)S
Table 27. Latam Pain Management Drugs Market, by Opioids, by Country, 2019-2027 ($Million)
Table 28. Latam Pain Management Drugs Market, by Opioids, by Country, 2019-2027 (Million Units)
Table 29. Latam Pain Management Drugs Market, by Non-Narcotic Analgesics, by Country, 2019-2027 ($Million)
Table 30. Latam Pain Management Drugs Market, by Non-Narcotic Analgesic, by Country, 2019-2027 (Million Units)S
Table 31. Latam Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 32. Latam Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)S
Table 33. Latam Pain Management Drugs Market, by Arthritic Pain, by Country, 2019-2027 ($Million)
Table 34. Latam Pain Management Drugs Market, by Arthritic Pain, by Country, 2019-2027 (Million Units)
Table 35. Latam Pain Management Drugs Market, by Neuropathic Pain, by Country, 2019-2027 ($Million)S
Table 36. Latam Pain Management Drugs Market, by Neuropathic Pain, by Country, 2019-2027 (Million Units)
Table 37. Latam Pain Management Drugs Market, by Cancer Pain, by Country, 2019-2027 ($Million)
Table 38. Latam Pain Management Drugs Market, by Cancer Pain, by Country, 2019-2027 (Million Units)
Table 39. Latam Pain Management Drugs Market, by Chronic Back Pain, by Country, 2019-2027 ($Million)
Table 40. Latam Pain Management Drugs Market, by Chronic Back Pain, by Country, 2019-2027 (Million Units)
Table 41. Latam Pain Management Drugs Market, by Post-Operative Pain, by Country, 2019-2027 ($Million)
Table 42. Latam Pain Management Drugs Market, by Post-Operative Pain, by Country, 2019-2027 (Million Units)
Table 43. Latam Pain Management Drugs Market, by Migraine, by Country, 2019-2027 ($Million)
Table 44. Latam Pain Management Drugs Market, by Migraine, by Country, 2019-2027 (Million Units)
Table 45. Latam Pain Management Drugs Market, by Fibromyalgia, by Country, 2019-2027 ($Million)
Table 46. Latam Pain Management Drugs Market, by Fibromyalgia, by Country, 2019-2027 (Million Units)
Table 47. Latam Pain Management Drugs Market, by Bone Fracture, by Country, 2019-2027 ($Million)
Table 48. Latam Pain Management Drugs Market, by Bone Fracture, by Country, 2019-2027 (Million Units)
Table 49. Latam Pain Management Drugs Market, by Muscle Sprain/Strain, by Country, 2019-2027 ($Million)
Table 50. Latam Pain Management Drugs Market, by Sprain/Strain, by Country, 2019-2027 (Million Units)
Table 51. Latam Pain Management Drugs Market, by Acute Appendicitis, by Country, 2019-2027 ($Million)
Table 52. Latam Pain Management Drugs Market, by Acute Appendicitis, by Country, 2019-2027 (Million Units)
Table 53. Latam Pain Management Drugs Market, by Others, by Country, 2019-2027 ($Million)
Table 54. Latam Pain Management Drugs Market, by Others, by Country, 2019-2027 (Million Units)
Table 55. Latam Pain Management Drugs Market, by Country, 2019-2027 ($Million)
Table 56. Latam Pain Management Drugs Market, by Country, 2019-2027 (Million Units)
Table 57. Latam Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 58. Latam Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 59. Latam Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 60. Latam Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 61. Brazil Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 62. Brazil Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 63. Brazil Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 64. Brazil Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 65. Argentina Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 66. Argentina Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 67. Argentina Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 68. Argentina Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 69. Colombia Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 70. Colombia Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 71. Colombia Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 72. Colombia Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 73. Peru Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 74. Peru Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 75. Peru Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 76. Peru Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 77. Chile Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 78. Chile Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 79. Chile Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 80. Chile Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 81. Ecuador Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 82. Ecuador Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 83. Ecuador Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 84. Ecuador Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 85. Panama Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 86. Panama Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 87. Panama Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 88. Panama Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 89. Rest of Latin America Pain Management Drugs Market, by Drug Class, 2019-2027 ($Million)
Table 90. Rest of Latin America Pain Management Drugs Market, by Drug Class, 2019-2027 (Million Units)
Table 91. Rest of Latin America Pain Management Drugs Market, by Indication, 2019-2027 ($Million)
Table 92. Rest of Latin America Pain Management Drugs Market, by Indication, 2019-2027 (Million Units)
Table 93. Abbott: Company Snapshot
Table 94. Abbott: Oerating Segment
Table 95. Abbott: Product Portfolio
Table 96. Axon Pharma: Company Snapshot
Table 97. Axon Pharma: Product Portfolio
Table 98. Eli Lilly: Company Snapshot
Table 99. Lilly: Operating Segments
Table 100. Eli Lilly: Product Portfolio
Table 101. Eli Lilly: Key Strategic Moves and Developments
Table 102. Grünenthal: Company Snapshot
Table 103. Grünenthal: Product Portfolio
Table 104. Gsk: Company Snapshot
Table 105. Gsk: Operating Segments
Table 106. Gsk: Product Portfolio
Table 107. J&J: Company Snapshot
Table 108. J&J: Operating Business Segments
Table 109. J&J: Product Portfolio
Table 110. Merck & Co., Inc.: Company Snapshot
Table 111. Merck & Co., Inc.: Operating Segments
Table 112. Merck & Co., Inc.: Product Portfolio
Table 113. Merck & Co., Inc.: Key Strategic Moves and Developments
Table 114. Mylan: Company Snapshot
Table 115. Mylan: Operating Business Segments
Table 116. Mylan: Product Portfolio
Table 117. Novartis: Company Snapshot
Table 118. Novartis: Operating Segments
Table 119. Novartis: Product Portfolio
Table 120. Pfizer: Company Snapshot
Table 121. Pfizer: Oerating Segment
Table 122. Pfizer: Product Portfolio
Table 123. Sanofi: Company Snapshosst
Table 124. Sanofi: Operating Segments
Table 125. Sanofi: Product Portfolio

List of Figures
Figure 01. Latam Pain Management Drugs Market Segmentation
Figure 02. Top Winning Strategies, 2017-2020
Figure 03. Top Winning Strategies: by Development , 2017-2020
Figure 04. Top Winning Strategies: by Year, 2017-2020
Figure 05. Top Player Postioning, 2019
Figure 06. Moderate Bargaining Power of Suppliers
Figure 07. Moderate Bargaining Power of Buyers
Figure 08. Moderate Threat of Substitutess
Figure 09. Modearte Threat of New Entrants
Figure 10. Moderate Competitive of Rivalry
Figure 11. Driver, Restraints and Opportunities
Figure 12. Latam Pain Management Drugs Market, 2020-2027 ($Million)
Figure 13. Brazil Pain Management Drugs Market, 2020-2027 ($Million)
Figure 14. Argentina Pain Management Drugs Market, 2020-2027 ($Million)
Figure 15. Colombia Pain Management Drugs Market, 2020-2027 ($Million)
Figure 16. Peru Pain Management Drugs Market, 2020-2027 ($Million)
Figure 17. Chile Pain Management Drugs Market, 2020-2027 ($Million)
Figure 18. Ecuador Pain Management Drugs Market, 2020-2027 ($Million)
Figure 19. Panama Pain Management Drugs Market, 2020-2027 ($Million)
Figure 20. Rest of Latin America Pain Management Drugs Market, 2020-2027 ($Million)
Figure 21. Abbott: Net Sales, 2017-2019 ($Million)
Figure 22. Abbott: Revenue Share, by Segment, 2019 (%)
Figure 23. Abbott: Revenue Share, by Region, 2019 (%)
Figure 24. Eli Lilly: Net Sales, 2017-2019 ($Million)
Figure 25. Eli Lilly: Revenue Share, by Region, 2019 (%)
Figure 26. Grünenthal: Net Sales, 2017-2019 ($Million)
Figure 27. Gsk: Net Sales, 2017-2019 ($Million)
Figure 28. Gsk: Revenue Share, by Segment, 2019 (%)
Figure 29. Gsk: Revenue Share, by Region, 2019 (%)
Figure 30. J&J: Net Sales, 2017-2019 ($Million)
Figure 31. J&J: Revenue Share, by Segment, 2019 (%)
Figure 32. J&J: Revenue Share, by Region, 2019 (%)
Figure 33. Merck & Co. Inc. : Net Sales, 2017-2019 ($Million)
Figure 34. Merck & Co. Inc. : Revenue Share, by Segment, 2019 (%)
Figure 35. Merck & Co. Inc. : Revenue Share, by Region, 2019 (%)
Figure 36. Mylan: Net Sales, 2017-2019 ($Million)
Figure 37. Mylan: Revenue Share, by Region, 2019 (%)
Figure 38. Novartis: Net Sales, 2017-2019 ($Million)
Figure 39. Novartis: Revenue Share, by Segment, 2019 (%)
Figure 40. Novartis: Revenue Share, by Region, 2019 (%)
Figure 41. Pfizer: Net Sales, 2017-2019 ($Million)
Figure 42. Pfizer: Revenue Share, by Segment, 2019 (%)
Figure 43. Pfizer: Revenue Share, by Region, 2019 (%)
Figure 44. Sanofi: Net Sales, 2017-2019 ($Million)
Figure 45. Sanofi: Revenue Share, by Segment, 2019 (%)
Figure 46. Sanofi: Revenue Share, by Region, 2019 (%)
Note: Product cover images may vary from those shown

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll